Pseudovirus

ALL Pseudovirus

Filter By

Product Type

Product Category

Target Pathogen

Product Target

Application

Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1)

Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1): A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) that are available for your initial testing from the Sudan Ebola strain (Genebank: YP_138523.1) These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs.

Formulation & Storage: Store at -80°C.
Notes & Usage Guidelines:
Size: 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP

This Ebola Virus like particles is intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.

Price:

$4,100.00

Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2)

Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2): A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) from the Zaire strain that are available for your initial testing. These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs.

Formulation & Storage: Available upon request Store at -80°C.
Notes & Usage Guidelines:
Size: 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP

Virus-like particles (VLP’s) expressing recombinant GP (Glycoprotein), N (Nucleoporin), and PV40 matrix protein structural proteins This Ebola Virus like particles is intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of the datasheet is sent along with the products. Please refer to it for detailed information. Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$4,100.00

Ebola virus-like particles (EBOV VLP) (Zaire)

Virus-like Particles (VLP’s) expressing recombinant Ebola virus (EBOV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). Are produced in Sf9 insect cells through infection with a recombinant baculovirus. Relevance: These VLP’s mimic Ebola virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and tool to enhance filovirus research.

Pathogen Strain: Zaire
Purification: Column chromatography
Expression: SF9 cells
Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Please note: After thawing, VLP’s tend to sediment to bottom of the tube and appear as aggregate pellet. Resuspend by gentle vortexing or pipetting up and down.

Price:

Original price was: $656.00.Current price is: $590.40.

HIV Virus like particle (Human Immunodeficiency Virus)

HIV Virus like particle (VLP’s) expressing recombinant structural proteins Safe for use in BSL-2 facilities.

Formulation & Storage: Store at -80°C.
Notes & Usage Guidelines:
Size: 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP

Intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$4,100.00

Influenza H5 Pseudovirus

Lentivirus vector pseudotyped with Influenza H5 hemagglutinin. Lentiviral vectors are self-inactivating (SIN), and thus restrict mRNA production from integrating vectors to the internal promoter, severely reducing full-length vector transcripts. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Formulation & Storage: Supplied in phosphate buffered saline (PBS). Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: 2.2 x 105 RLU/µL
Usage Estimates*: Approximately 1 mL can be used to perform 2,,000 reactions or 20 x 96-well plates.
Reporter: Luciferase

Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$1,294.00

Influenza H7 Pseudovirus

Lentivirus vector pseudotyped with Influenza H7 hemagglutinin. Lentiviral vectors are self-inactivating (SIN), and thus restrict mRNA production from integrating vectors to the internal promoter, severely reducing full-length vector transcripts. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Formulation & Storage: Supplied in phosphate buffered saline (PBS). Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: 2.2 x 105 RLU/µL
Usage Estimates*: Approximately 1 mL can be used to perform 2,,000 reactions or 20 x 96-well plates.
Reporter: Luciferase

Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$1,294.00

Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1)

Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1) : A novel rapid hybrid alpha-pseudovirus for Marburg (MARV) (HA-MARV) MARV001 Isolate that is available for your initial testing. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. HA-MARV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entryinhibiting drugs.

Formulation & Storage: Available upon request Store at -80°C.
Notes & Usage Guidelines:
Size: 1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP
Applications:
- Marburg pseudovirus transduction of target cells for viral entry and functional studies
- Rapid Anti-Marburg drug screening
- Rapid Anti-Marburg neutralizing antibody

This Marburg virus like particles is Intended for research use only, not for human, therapeutic, or diagnostic applications. Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$4,100.00

Marburg-Musoke virus-like particles (MMARV VLP)

Virus-like Particles (VLP’s) expressing recombinant Marburg (MARV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40).

Marburg Strain: Musoke
These VLP’s are produced in Sf9 insect cells through infection with a recombinant baculovirus.
Relevance: Since these VLP’s mimic MARV (Musoke) virus but do not contain genetic material, thus are not infectious making an ideal candidate as a vaccine and a tool to enhance filovirus research.
Notes & Usage Guidelines: Please note: After thawing, VLP’s tend to sediment to the bottom of the tube and appear as aggregate pellet. VLP’s can be resuspended by gentle vortexing or by pipetting up and down, before use. Also, subaliquoting is recommended to avoid repeated freeze/thaw cycles.

Price:

Original price was: $656.00.Current price is: $590.40.

Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type

Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type: hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERS-CoV-2) for Wild Type strain. The hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERSCoV-2) is a newly developed MARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)pseudoviruses, Ha-MERS-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of MERS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle.

Formulation & Storage: Store at -80°C.
Notes & Usage Guidelines:
Size:
•60X concentrated 5 x 100 µL
•1x Conc. 25 x 200uL (~100 wells)
Reporter: Available with Firefly luciferase, GFP, or RFP

Applications: • Screening and quantification of anti-coronavirusneutralizing antibodies • Anti-coronavirus drug screening • Quantification of viral mutants’ infectivity • Identification of host co-factors and restriction factors of coronaviruses Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

Nipah Virus-like particles (HA-NiV)

A novel rapid hybrid alpha-pseudovirus for Nipah virus (HA-NiV). HA-NiV particles are pseudoviruses assembled from the structural proteins of the Nipah virus, Fusion (F), Glycoprotein (G), Matrix (M), and Nucleocapsid (N) proteins and package an alphaviral vector for reporter gene expression. The alphapseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. Formulation & Storage: Store at -80°C. Notes & Usage Guidelines: Size: 1X concentrated 25 x 200 µL ~100 wells/96 well plate Reporter: Available with Firefly luciferase, GFP, or RFP Applications

Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening

Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$4,100.00

rVSV pseudotyped Marburg Virus GP (Angola Strain)

Recombinant Vesicular Stomatitis Virus pseudotyped MARV-Angola glycoprotein (rVSV pseudotyped MARVAngola GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Marburg virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment. Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C. Notes & Usage Guidelines:

Recommended Dilution: 1: 800
Luciferase Units for Assays: 30,000
Reporter: Luciferase

Price:

Original price was: $656.25.Current price is: $590.62.

rVSV pseudotyped Sudan Virus GP (Boniface Strain)

Recombinant Vesicular Stomatitis Virus pseudotyped Sudan glycoprotein (rVSV pseudotyped SUDV GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV pseudotypes containing the envelope glycoprotein of Sudan virus. Since the infectivity of rVSV pseudotyped SUDV GP is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Notes & Usage Guidelines:
Recommended Dilution Range: 1: 40-1:80
Luciferase Units for Assays: 20,000-40,000

Price:

Original price was: $656.25.Current price is: $590.62.

rVSV pseudotyped Sudan Virus GP (Gulu Strain)

rVSV pseudotyped Sudan Virus GP (Gulu Strain) or Recombinant Vesicular Stomatitis Virus pseudotyped Sudan Virus Gulu glycoprotein (rVSV-SUDV-Gulu-GP)) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSVpseudotyped virus containing the envelope glycoprotein of Sudan virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.

Price:

Original price was: $656.25.Current price is: $590.62.

rVSV-pseudotyped Ebola virus GP (rVSV-EBOV-GP)

Recombinant Vesicular Stomatitis Virus (rVSV) pseudotyped with Ebola virus glycoprotein (rVSV-EBOV-GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Ebola virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.

Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Notes & Usage Guidelines:
Recommended Dilution: 1:40
Luciferase Units for Assays: 30,000
Reporter: Luciferase

Price:

Original price was: $656.25.Current price is: $590.62.

SARS-CoV-2 Virus Like Particles (Ha-CoV2) Delta Plus (AY.2)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta Plus (AY.2): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Delta Plus (AY.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike T19R, Spike V70F, Spiked del157/158, Spike A222V, Spike K417N, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N Size: 25 X 200 µL ~100 wells/96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (Alpha (B.1.1.7))

SARS-CoV-2 Virus Like Particles (Alpha (B.1.1.7)) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (B.1.1.207)

Virus Like Particles for SARS-CoV-2 strain: B.1.1.207 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2, Virus Like Particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike D614G, Spike E484K, Spike P681H Size: 25 X 200 µL ~100 wells/96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP Intended for research use only, not for human, therapeutic, or diagnostic applications

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (D614G Single AA Mutant)

The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike D614G Size(s):

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications

Price:

$1,490.00 – $2,350.00

Ebola virus-like particles (EBOV VLP) (Zaire)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Kappa (B.1.617.1)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2)

SARS-CoV-2, Virus Like Particles (B.1.1.207)

SARS-CoV-2, Virus Like Particles (Alpha (B.1.1.7))

Pseudovirus

ALL Pseudovirus

Filter By

Product Type

Product Category

Target Pathogen

Product Target

Application

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

Price:

FEATURED PRODUCTS

Related products

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Epsilon (B.1.427/429)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Epsilon (B.1.429)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258)

SARS-CoV-2, Virus Like Particles (B.1.1.207)

Reagents

In-Vitro Services

Animal Services

By Disease Target

Services